Nektar Therapeutics (NKTR) Cash from Operations (2010 - 2026)

Nektar Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 44298000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 9.69% year-over-year to 44298000.0 in Q1 2026; TTM through Mar 2026 was 203756000.0, a 15.2% decrease from a year earlier, with the FY2025 full-year figure at 208511000.0, down 18.67% from the prior year.
• Cash from Operations advanced to 44298000.0 in Q1 2026 per NKTR's latest filing, from 64959000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 37702000.0 in Q2 2024 and bottomed at 88424000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 48761000.0 (2025), against an average of 54419470.59.
• Across the five-year window, Cash from Operations surged 61.92% in 2022 and sank 40.64% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 57703000.0 in 2022, then grew by 18.47% to 47047000.0 in 2023, then increased by 1.83% to 46187000.0 in 2024, then sank by 40.64% to 64959000.0 in 2025, then jumped by 31.81% to 44298000.0 in 2026.
• Per Business Quant, the three latest NKTR Cash from Operations figures stand at 44298000.0 (Q1 2026), 64959000.0 (Q4 2025), and 48761000.0 (Q3 2025).